H
Hunter C. Champion
Researcher at Johns Hopkins University
Publications - 275
Citations - 23191
Hunter C. Champion is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pulmonary hypertension & Adrenomedullin. The author has an hindex of 74, co-authored 275 publications receiving 21959 citations. Previous affiliations of Hunter C. Champion include Johns Hopkins University School of Medicine & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
PDE5A Inhibitor Treatment of Persistent Pulmonary Hypertension After Mechanical Circulatory Support
Ryan J. Tedford,Anna R. Hemnes,Stuart D. Russell,Ilan S. Wittstein,Mobusher Mahmud,Ari L. Zaiman,Stephen C. Mathai,David R. Thiemann,Paul M. Hassoun,Reda E. Girgis,Jonathan B. Orens,Ashish S. Shah,David D. Yuh,John V. Conte,Hunter C. Champion +14 more
TL;DR: In patients with persistent PH after recent LVAD placement, phosphodiesterase type 5A inhibition in this open-label trial resulted in a significant decrease in PVR when compared with control patients.
Journal ArticleDOI
FIZZ1/RELMα, a Novel Hypoxia-Induced Mitogenic Factor in Lung With Vasoconstrictive and Angiogenic Properties
TL;DR: The PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF, which increased pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
Journal ArticleDOI
Compartmentalization of Cardiac β-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5
Eiki Takimoto,Diego F. Belardi,Carlo G. Tocchetti,Susan Vahebi,Gianfrancesco Emanuele Cormaci,Elizabeth A. Ketner,An L. Moens,Hunter C. Champion,David A. Kass +8 more
TL;DR: Regulation of cardiac &bgr;-adrenergic response by cGMP is specifically linked to a nitric oxide–synthesis/PDE-5–hydrolyzed pool signaling via protein kinase G.
Journal ArticleDOI
Phosphodiesterase regulation of nitric oxide signaling
TL;DR: Growing evidence supports an important role of several PDEs, including PDE1, PDE2, and PDE5, in the regulation of cGMP in both vascular smooth muscle and cardiac myocytes, and cross-signaling with NO-cGMP synthetic pathways that may be particularly helpful in treating certain disease states.
Journal ArticleDOI
PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.
TL;DR: It is demonstrated that PDE5 inhibition ameliorates RV hypertrophy and pulmonary fibrosis associated with intratracheal bleomycin in a manner that is associated with improved NOS coupling and a reduction in reactive oxygen species signaling.